

Therapeutic Area

Project Name	Modality	Target	Hit	Lead Series	Lead Opt	Pre-clinical	Clinical	Indication
Inflammation, Immunity & Infectious Diseases								
Medicinal supplement	Supplement	●	●	●	●	●	●	AI diseases / Type 1 Diabetes - PARTNERING IN PROGRESS
Novel COVID-19 vaccines and formulations	Vaccine	●	●	●	●	●	●	COVID-19
Novel reformulation and use of orlistat	Drug reprofile	●	●	●	●	●		Acute pancreatitis, critical care and organ failure
S1P receptor modulators	Small molecule	●	●	●				IBD
Novel NLRP3 inflammasome target	Small molecule	●	●	●				Inflammatory diseases
Novel cytokine selective agonist	Biologic	●	●	●	●			Lupus and other autoimmune diseases
Novel anti-CD80 antibodies as immunosuppressants	Antibody	●	●	●				Autoimmune diseases, inflammation
Oncology								
Dual-targeted PI3K/BET inhibitors	Small molecule	●	●	●	●			Haematological and solid cancers
Anti-CXCR1 mAb	Antibody	●	●	●	●			Myeloid-derived suppressor cell (MDSC) depletion/ inhibition
Inhibiting PTPN2 and PTPN1 for T cell therapy efficacy	Cell therapy	●						Solid tumours - Non-exclusive licence available
Modified CTLA4-fusion protein	Biologic	●	●	●				Immune stimulating
Anti-CCR8 mAb	Antibody	●	●	●	●			Tumour infiltrating Treg depletion
Cardiovascular, Fibrosis & Metabolic Diseases								
Selective AT2 receptor agonists	Peptide	●	●	●				Renal, liver, kidney, lung and cardiac fibrosis
Glucocorticoid receptor inhibitors	Small molecule	●	●					Obesity
Anti-CX3CR1 mAb	Antibody	●	●	●				NASH, CKD, Atherosclerosis
A1 receptor biased agonists	Small molecule	●	●	●				Heart failure post MI
Anti-cannabinoid receptor 1 mAb	Antibody	●	●	●				NASH
Selective PAR2 NAMs	Small molecule	●	●	●				Fibrosis
FPR2-biased agonist	Small molecule	●	●					PAH and other indications
FPR1-biased agonist	Small molecule	●	●	●				Heart failure (HFpEF, MI)
Sustained glucose-responsive insulin delivery	Drug delivery	●	●	●				Diabetes
Novel PKD target	Small molecule	●	●					Polycystic Kidney Diseases including ADPKD

Therapeutic Pipeline & Related Technologies

Therapeutic Area	Project Name	Modality	Target	Hit	Lead Series	Lead Opt	Pre-clinical	Clinical	Indication
	CNS								
	Extended release formulation - sodium selenate	Small molecule	●	●	●	●	●	●	Neurological and neurodegenerative diseases
	Targeted GPCR modulators (undisclosed target)	Small molecule	●	●	●				Schizophrenia
	Rare Diseases / Other								
	Recombinant plasminogen	Biologic	●	●	●	●			Type I/II plasminogen deficiency, wound healing and diseases associated with fibrin accumulation
	Fc-plasminogen	Biologic	●	●	●	●			
	Novel therapeutic for skeletal muscle regeneration	Biologic	●	●	●				DMD and other dystrophies, acute muscle injuries
	Inhaled oxytocin	Peptide	●	●	●	●	●	●	Post-partum haemorrhage

	Other Biomedical Opportunities	Regenerative Medicine	Drug Delivery	Biomarker Diagnostics	Other / Discovery	Application Area
Technology	iBlastoids + derived cell lines	●			●	Cell therapy, disease models drug discovery/screening, toxicity testing
	'Corrected' iPSCs	●			●	
	Lipopeptide-based nanoparticle delivery platform		●			Gene/ mRNA delivery – muscle/ other
	Lipid nanoparticle delivery platform		●			Gene/ mRNA delivery - enhanced vaccine and immune response
	Stem cell/ biomolecule delivery platform		●			Peptide-based; functionally tuneable, preserves function
	Metal organic framework (MOF) antibody-based bio-composites		●			Platform technology for antibody-based delivery/ conjugation
	Biomarker assay for Diabetic Kidney Disease (DKD)			●		Prognostic and diagnostic
	Drug discovery platforms				●	TCR, GPCR antibodies, MHC peptides, etc.
	mRNA-binding platform				●	RNA drug discovery library generation